Literature DB >> 29155994

Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life.

Kathleen Morrisroe1,2, Vijaya Sudararajan1, Wendy Stevens2, Joanne Sahhar3, Jane Zochling4, Janet Roddy5, Susanna Proudman6,7, Mandana Nikpour1,2.   

Abstract

Objective: To evaluate work productivity and its economic burden in SSc patients.
Methods: Consecutive SSc patients enrolled in the Australian Scleroderma Cohort Study were mailed questionnaires assessing employment (Workers' Productivity and Activity Impairment Questionnaire and a custom-made questionnaire) and health-related quality of life (HRQoL) (36-item Short Form Health Survey and Patient-Reported Outcomes Measurement Information System 29). Linear regression methods were used to determine factors associated with work productivity.
Results: Among 476 patients submitting responses, 55.2% <65 years of age were employed. Unemployed patients were older at the time of survey completion (57.1 vs 53.7 years; P < 0.001) and had longer disease duration from first SSc clinical manifestation (16.2 vs 14.9 years; P = 0.01) than employed patients. The mean age at unemployment onset was 13.2 years below the average Australian retirement age. Of those working in the week prior to completing the survey, 16.0% reported missing work (absenteeism) due to their SSc, accounting for 32.9% of their working week. Reduced productivity while at work (presenteeism) accounted for 22% of their working week. Annual costs per patient as a consequence of unemployment and reduced productivity equated to a total of AUD$67 595.40. Factors independently associated with reduced work productivity were presence of synovitis and sicca symptoms, while tertiary education protected against work impairment. Patients with low HRQoL scores also had low work productivity.
Conclusion: SSc is associated with considerable unemployment and reduced productivity, which in turn is associated with a substantial economic burden and poor HRQoL. Raising awareness and identifying modifiable factors are possible ways of reducing this burden.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  economic burden; scleroderma; systemic sclerosis; unemployment; work productivity

Mesh:

Year:  2018        PMID: 29155994     DOI: 10.1093/rheumatology/kex362

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

Review 1.  A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

Authors:  Lesley Ann Saketkoo; Tracy Frech; Cecília Varjú; Robyn Domsic; Jessica Farrell; Jessica K Gordon; Carina Mihai; Nora Sandorfi; Lee Shapiro; Janet Poole; Elizabeth R Volkmann; Monika Lammi; Kendra McAnally; Helene Alexanderson; Henrik Pettersson; Faye Hant; Masataka Kuwana; Ami A Shah; Vanessa Smith; Vivien Hsu; Otylia Kowal-Bielecka; Shervin Assassi; Maurizio Cutolo; Cristiane Kayser; Victoria K Shanmugam; Madelon C Vonk; Kim Fligelstone; Nancy Baldwin; Kerri Connolly; Anneliese Ronnow; Beata Toth; Maureen Suave; Sue Farrington; Elana J Bernstein; Leslie J Crofford; László Czirják; Kelly Jensen; Monique Hinchclif; Marie Hudson; Matthew R Lammi; Jennifer Mansour; Nadia D Morgan; Fabian Mendoza; Mandana Nikpour; John Pauling; Gabriela Riemekasten; Anne-Marie Russell; Mary Beth Scholand; Elise Seigart; Tatiana Sofia Rodriguez-Reyna; Laura Hummers; Ulrich Walker; Virginia Steen
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-09-15       Impact factor: 4.991

Review 2.  Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS).

Authors:  Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-07-01       Impact factor: 4.991

3.  Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes.

Authors:  Alain Lescoat; Susan L Murphy; David Roofeh; John D Pauling; Michael Hughes; Robert Sandler; François Zimmermann; Rachel Wessel; Whitney Townsend; Lorinda Chung; Christopher P Denton; Peter A Merkel; Virginia Steen; Yannick Allanore; Francesco Del Galdo; Dominique Godard; David Cella; Sue Farrington; Maya H Buch; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-10-05

Review 4.  Managing Fatigue in Patients With Interstitial Lung Disease.

Authors:  Vivienne Kahlmann; Catharina C Moor; Marlies S Wijsenbeek
Journal:  Chest       Date:  2020-05-07       Impact factor: 9.410

5.  Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis.

Authors:  Ahmet Karatas; Burak Oz; Cigdem Celik; Zeynel Abidin Akar; Ramazan Fazil Akkoc; Ebru Onalan Etem; Adile Ferda Dagli; Suleyman Serdar Koca
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.379

6.  Work Productivity and Economic Burden of Systemic Sclerosis in a Multiethnic Asian Population.

Authors:  Ling Xiang; Sandra M Y Kua; Andrea H L Low
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-03-12       Impact factor: 5.178

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.